 Myrexis (MYRX) is an early-stage pharmaceutical company that focuses on the development of anti-cancer drugs whose shares are trading -41.00 % from their 52-Wk High ($ 4.22).
|
|
Read more...
|
 Below is a look at some of the headlines for companies that made news in the healthcare sector on May 23, 2012.
|
|
Read more...
|
 Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is an oncology drug developer that is testing a plethora of drug candidates for various types of cancers. For the time being, the market seems to be focusing on the development of the drug Perifosine, which is a phase III treatment for advanced metastatic colorectal cancer and multiple myeloma.
|
|
Read more...
|
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 22, 2012.
|
|
Read more...
|
 Recently considered biotech’s immunotherapy darling, shares of Dendreon Corporation have been taking a beating. Does this mean the end of the road or opportunity for others in the same space?
|
|
Read more...
|
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 21, 2012.
|
|
Read more...
|
 Investors may be a bit weary of jumping into PROLOR Biotech (PBTH) after the company announced the closing an underwritten public offering, but that hasn't kept billionaire Phil Frost-- chairman of generic drugmaker Teva Pharmaceutical Industries (NASDAQ:TEVA)-- from buying another big chunk of the company.
|
|
Read more...
|
